Review



human nsclc cell lines a549 and pc9  (Beyotime)


Bioz Verified Symbol Beyotime is a verified supplier
Bioz Manufacturer Symbol Beyotime manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Beyotime human nsclc cell lines a549 and pc9
    Human Nsclc Cell Lines A549 And Pc9, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nsclc+cell+lines+a549+and+pc9/a549+cells/pm40279954-46-0-9
    Average 90 stars, based on 1 article reviews
    human nsclc cell lines a549 and pc9 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Inhibition of NSUN3 suppresses immune escape in non-small cell lung cancer through stabilizing PD-L1 in a 5-methyladenosine dependent way.
    Article Snippet: .. Human NSCLC cell lines (A549 and PC9) obtained from Beyotime Company and human normal bronchial epithelial cell line HBE obtained from ATCC were cultured in DMEM supplemented with 10 % fetal bovine serum (FBS; Gibco) and 1 % penicillin/streptomycin (Beyotime). ..



    Similar Products

    human nsclc cell lines a549 and pc9  (Beyotime)
    90
    Beyotime human nsclc cell lines a549 and pc9
    Human Nsclc Cell Lines A549 And Pc9, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nsclc+cell+lines+a549+and+pc9/a549+cells/pm40279954-46-0-9
    Average 90 stars, based on 1 article reviews
    human nsclc cell lines a549 and pc9 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    human nsclc cell lines pc9 and a549  (China Center for Type Culture Collection)
    90
    China Center for Type Culture Collection human nsclc cell lines pc9 and a549
    MiR-26b was downregulated in cisplatin-resistant NSCLC cells. ( A ) CCK-8 assays were performed to detect the drug sensitivity of <t>A549,</t> A549/R, PC9 and PC9/R cells to cisplatin (0–120 μM). ( B ) IC50 of cisplatin to A549, A549/R, PC9 and PC9/R cells was calculated according to the cell viability curve. ( C ) Quantitative real-time PCR analysis was used to compare the miR-26b level between cisplatin-resistant NSCLC cells and routine NSCLC cells. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: NSCLC, non-small cell lung cancer; CCK-8, Cell Counting Kit-8; IC50, 50% inhibiting concentration.
    Human Nsclc Cell Lines Pc9 And A549, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nsclc+cell+lines+a549+and+pc9/a549+cells/pmc06751336-30-6-11
    Average 90 stars, based on 1 article reviews
    human nsclc cell lines pc9 and a549 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MiR-26b was downregulated in cisplatin-resistant NSCLC cells. ( A ) CCK-8 assays were performed to detect the drug sensitivity of A549, A549/R, PC9 and PC9/R cells to cisplatin (0–120 μM). ( B ) IC50 of cisplatin to A549, A549/R, PC9 and PC9/R cells was calculated according to the cell viability curve. ( C ) Quantitative real-time PCR analysis was used to compare the miR-26b level between cisplatin-resistant NSCLC cells and routine NSCLC cells. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: NSCLC, non-small cell lung cancer; CCK-8, Cell Counting Kit-8; IC50, 50% inhibiting concentration.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: MiR-26b was downregulated in cisplatin-resistant NSCLC cells. ( A ) CCK-8 assays were performed to detect the drug sensitivity of A549, A549/R, PC9 and PC9/R cells to cisplatin (0–120 μM). ( B ) IC50 of cisplatin to A549, A549/R, PC9 and PC9/R cells was calculated according to the cell viability curve. ( C ) Quantitative real-time PCR analysis was used to compare the miR-26b level between cisplatin-resistant NSCLC cells and routine NSCLC cells. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: NSCLC, non-small cell lung cancer; CCK-8, Cell Counting Kit-8; IC50, 50% inhibiting concentration.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: CCK-8 Assay, Real-time Polymerase Chain Reaction, Cell Counting, Concentration Assay

    MiR-26b partially reversed the cisplatin resistance of PC9/R and A549/R. ( A ) Transfection with miR-26b mimics increased the miR-26b level in PC9/R and A549/R cells. ( B ) Transfection with miR-26b mimics increased the sensitivity of PC9/R and A549/R cells to cisplatin (15 μM). ( C ) Transfection with anti-miR-26b decreased the miR-26b level in PC9 and A549 cells. ( D ) Transfection with anti-miR-26b decreased the sensitivity of PC9 and A549 cells to cisplatin (15 μM). Notes: Data are expressed as mean±SD. * P <0.05 vs NCO group, # P <0.05 vs Cisplatin+NCO group. Abbreviation: NCO, negative control oligonucleotide.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: MiR-26b partially reversed the cisplatin resistance of PC9/R and A549/R. ( A ) Transfection with miR-26b mimics increased the miR-26b level in PC9/R and A549/R cells. ( B ) Transfection with miR-26b mimics increased the sensitivity of PC9/R and A549/R cells to cisplatin (15 μM). ( C ) Transfection with anti-miR-26b decreased the miR-26b level in PC9 and A549 cells. ( D ) Transfection with anti-miR-26b decreased the sensitivity of PC9 and A549 cells to cisplatin (15 μM). Notes: Data are expressed as mean±SD. * P <0.05 vs NCO group, # P <0.05 vs Cisplatin+NCO group. Abbreviation: NCO, negative control oligonucleotide.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: Transfection, Negative Control

    TAZ is the target of miR-26b in NSCLC. ( A ) TAZ was commonly predicted to be the target of miR-26b on TargetScan, miRanda and PicTar databases. ( B ) Protein level of TAZ in A549, A549/R, PC9 and PC9/R cells was evaluated by Western blot analysis. ( C ) Transfection with miR-26b decreased the protein level of TAZ in A549/R and PC9/R cells. ( D ) Transfection with anti-miR-26b increased the protein level of TAZ in A549 and PC9 cells. ( E ) After co-transfection with miR-26b (or anti-miR-26b) and pGL3 luciferase reporters carrying wild type TAZ 3ʹ-UTR (or pGL3 luciferase reporters carrying mutant type TAZ 3ʹ-UTR), luciferase activities were measured by using Dual-Luciferase Reporter Assay System according to the manufacturer’s instruction. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: TAZ, Tafazzin; NSCLC, non-small cell lung cancer; 3ʹ-UTR, 3ʹ-untranslated region; NCO, negative control oligonucleotide.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: TAZ is the target of miR-26b in NSCLC. ( A ) TAZ was commonly predicted to be the target of miR-26b on TargetScan, miRanda and PicTar databases. ( B ) Protein level of TAZ in A549, A549/R, PC9 and PC9/R cells was evaluated by Western blot analysis. ( C ) Transfection with miR-26b decreased the protein level of TAZ in A549/R and PC9/R cells. ( D ) Transfection with anti-miR-26b increased the protein level of TAZ in A549 and PC9 cells. ( E ) After co-transfection with miR-26b (or anti-miR-26b) and pGL3 luciferase reporters carrying wild type TAZ 3ʹ-UTR (or pGL3 luciferase reporters carrying mutant type TAZ 3ʹ-UTR), luciferase activities were measured by using Dual-Luciferase Reporter Assay System according to the manufacturer’s instruction. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: TAZ, Tafazzin; NSCLC, non-small cell lung cancer; 3ʹ-UTR, 3ʹ-untranslated region; NCO, negative control oligonucleotide.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: Western Blot, Transfection, Cotransfection, Luciferase, Mutagenesis, Reporter Assay, Negative Control

    Restoration of miR-26b expression partially reversed the cisplatin resistance of NSCLC through suppression of TAZ. ( A ) Transfection with TAZ plasmid inhibited the sensitization of miR-26b on cisplatin-induced (15 μM) cytotoxicity against A549/R and PC9/R. ( B ) Transfection with TAZ siRNA increased the sensitivity of A549/R and PC9/R cells to cisplatin (15 μM) treatment. ( C ) Transfection with TAZ plasmid decreased the sensitivity of A549 and PC9 cells to cisplatin (15 μM) treatment. Notes: Data are expressed as mean±SD. * P <0.05 vs NCO group, # P <0.05 vs Cisplatin+NCO group, & P <0.05 vs Cisplatin+miR-26b group. Abbreviations: TAZ, Tafazzin; NSCLC, non-small cell lung cancer; NCO, negative control oligonucleotide.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: Restoration of miR-26b expression partially reversed the cisplatin resistance of NSCLC through suppression of TAZ. ( A ) Transfection with TAZ plasmid inhibited the sensitization of miR-26b on cisplatin-induced (15 μM) cytotoxicity against A549/R and PC9/R. ( B ) Transfection with TAZ siRNA increased the sensitivity of A549/R and PC9/R cells to cisplatin (15 μM) treatment. ( C ) Transfection with TAZ plasmid decreased the sensitivity of A549 and PC9 cells to cisplatin (15 μM) treatment. Notes: Data are expressed as mean±SD. * P <0.05 vs NCO group, # P <0.05 vs Cisplatin+NCO group, & P <0.05 vs Cisplatin+miR-26b group. Abbreviations: TAZ, Tafazzin; NSCLC, non-small cell lung cancer; NCO, negative control oligonucleotide.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: Expressing, Transfection, Plasmid Preparation, Negative Control

    MiR-26b mimics targets TAZ to enhance the cisplatin-dependent mitochondrial apoptosis in A549/R and PC9/R. ( A ) Transfection with miR-26b mimics promoted the collapse of MMP in A549/R and PC9/R cells which were under the cisplatin (15 μM) treatment. ( B ) Transfection with miR-26b mimics promoted the release of cytochrome c from mitochondria into cytosol of A549/R and PC9/R cells which were under the cisplatin (15 μM) treatment. ( C ) Transfection with miR-26b mimics promoted the cleavage of caspase-9 and caspase-3 in A549/R and PC9/R cells which were under the cisplatin (15 μM) treatment. ( D ) Transfection with miR-26b mimics increased the apoptotic rate of PC9/R and A549/R cells which were under the cisplatin (15 μM) treatment. Notes: Data are expressed as mean±SD. # P <0.05 vs Cisplatin+NCO group, & P <0.05 vs Cisplatin+miR-26b group. Abbreviations: TAZ, Tafazzin; MMP, mitochondrial membrane potential; NSCLC, non-small cell lung cancer; NCO, negative control oligonucleotide.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: MiR-26b mimics targets TAZ to enhance the cisplatin-dependent mitochondrial apoptosis in A549/R and PC9/R. ( A ) Transfection with miR-26b mimics promoted the collapse of MMP in A549/R and PC9/R cells which were under the cisplatin (15 μM) treatment. ( B ) Transfection with miR-26b mimics promoted the release of cytochrome c from mitochondria into cytosol of A549/R and PC9/R cells which were under the cisplatin (15 μM) treatment. ( C ) Transfection with miR-26b mimics promoted the cleavage of caspase-9 and caspase-3 in A549/R and PC9/R cells which were under the cisplatin (15 μM) treatment. ( D ) Transfection with miR-26b mimics increased the apoptotic rate of PC9/R and A549/R cells which were under the cisplatin (15 μM) treatment. Notes: Data are expressed as mean±SD. # P <0.05 vs Cisplatin+NCO group, & P <0.05 vs Cisplatin+miR-26b group. Abbreviations: TAZ, Tafazzin; MMP, mitochondrial membrane potential; NSCLC, non-small cell lung cancer; NCO, negative control oligonucleotide.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: Transfection, Membrane, Negative Control

    MiR-26b mimics reversed the cross-resistance of A549/R and PC9/R to carboplatin and oxaliplatin. ( A ) Cross-resistance of A549/R and PC9/R to carboplatin. ( B ) Cross-resistance of A549/R and PC9/R to oxaliplatin. ( C ) Transfection with miR-26b mimics decreased the IC50 of A549/R and PC9/R to carboplatin. ( D ) Transfection with miR-26b mimics decreased the IC50 of A549/R and PC9/R to oxaliplatin. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: IC50, 50% inhibiting concentration; NCO, negative control oligonucleotide.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: MiR-26b mimics reversed the cross-resistance of A549/R and PC9/R to carboplatin and oxaliplatin. ( A ) Cross-resistance of A549/R and PC9/R to carboplatin. ( B ) Cross-resistance of A549/R and PC9/R to oxaliplatin. ( C ) Transfection with miR-26b mimics decreased the IC50 of A549/R and PC9/R to carboplatin. ( D ) Transfection with miR-26b mimics decreased the IC50 of A549/R and PC9/R to oxaliplatin. Notes: Data are expressed as mean±SD. * P <0.05. Abbreviations: IC50, 50% inhibiting concentration; NCO, negative control oligonucleotide.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: Transfection, Concentration Assay, Negative Control

    Schema of the predicted mechanisms by which miR-26b partially reverses the cisplatin resistance of NSCLC. Cisplatin damages DNA of A549/R and PC9/R cells to provide the apoptosis signals. Meanwhile, miR-26b inhibits TAZ expression and thus reduces the stability of mitochondrial outer membrane. As the results, miR-26b facilitates the mitochondria collapse in cancer cells which are under the stress of cisplatin-provided apoptosis signals. Due to the mitochondria collapse, Δφ is decreased and the MOM permeability is induced. Subsequently, cytochrome c is released from the mitochondria into the cytosol followed by activation of effector caspases to cause the apoptosis of A549/R and PC9/R cells. Abbreviations: TAZ, Tafazzin; NSCLC, non-small cell lung cancer; Δφ, mitochondrial membrane potential; MOM, mitochondrial outer membrane.

    Journal: OncoTargets and therapy

    Article Title: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

    doi: 10.2147/OTT.S212649

    Figure Lengend Snippet: Schema of the predicted mechanisms by which miR-26b partially reverses the cisplatin resistance of NSCLC. Cisplatin damages DNA of A549/R and PC9/R cells to provide the apoptosis signals. Meanwhile, miR-26b inhibits TAZ expression and thus reduces the stability of mitochondrial outer membrane. As the results, miR-26b facilitates the mitochondria collapse in cancer cells which are under the stress of cisplatin-provided apoptosis signals. Due to the mitochondria collapse, Δφ is decreased and the MOM permeability is induced. Subsequently, cytochrome c is released from the mitochondria into the cytosol followed by activation of effector caspases to cause the apoptosis of A549/R and PC9/R cells. Abbreviations: TAZ, Tafazzin; NSCLC, non-small cell lung cancer; Δφ, mitochondrial membrane potential; MOM, mitochondrial outer membrane.

    Article Snippet: Human NSCLC cell lines PC9 and A549 were obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China) and cultured in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA).

    Techniques: Expressing, Membrane, Permeability, Activation Assay